GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Cyclically Adjusted PB Ratio

Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted PB Ratio : 16.17 (As of Dec. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-12-15), Vertex Pharmaceuticals's current share price is €440.55. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €27.25. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 16.17.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:VRTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 13.87   Med: 23.65   Max: 39.61
Current: 15.27

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 39.61. The lowest was 13.87. And the median was 23.65.

WBO:VRTX's Cyclically Adjusted PB Ratio is ranked worse than
93.67% of 600 companies
in the Biotechnology industry
Industry Median: 1.545 vs WBO:VRTX: 15.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share data for the three months ended in Sep. 2024 was €54.642. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €27.25 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.38 24.01 15.70 15.05 16.02

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.51 16.02 15.21 16.21 15.31

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=440.55/27.25
=16.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=54.642/133.0289*133.0289
=54.642

Current CPI (Sep. 2024) = 133.0289.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201412 3.606 99.070 4.842
201503 3.704 99.621 4.946
201506 3.264 100.684 4.313
201509 3.345 100.392 4.432
201512 3.503 99.792 4.670
201603 3.476 100.470 4.602
201606 3.526 101.688 4.613
201609 3.670 101.861 4.793
201612 4.416 101.863 5.767
201703 5.635 102.862 7.288
201706 5.931 103.349 7.634
201709 5.947 104.136 7.597
201712 6.769 104.011 8.657
201803 7.640 105.290 9.653
201806 9.021 106.317 11.288
201809 9.743 106.507 12.169
201812 15.278 105.998 19.174
201903 16.306 107.251 20.225
201906 17.481 108.070 21.518
201909 18.542 108.329 22.770
201912 21.146 108.420 25.946
202003 22.571 108.902 27.572
202006 25.669 108.767 31.395
202009 26.541 109.815 32.152
202012 27.475 109.897 33.258
202103 29.144 111.754 34.692
202106 29.458 114.631 34.186
202109 31.619 115.734 36.344
202112 35.125 117.630 39.723
202203 38.750 121.301 42.497
202206 44.094 125.017 46.920
202209 51.276 125.227 54.471
202212 51.101 125.222 54.287
202303 52.347 127.348 54.682
202306 55.389 128.729 57.239
202309 60.011 129.860 61.476
202312 62.559 129.419 64.304
202403 66.059 131.776 66.687
202406 53.197 132.554 53.388
202409 54.642 133.029 54.642

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.